替比夫定初治慢性乙型肝炎患者早期病毒学应答预测模型的建立

黄水文; 刘宝荣; 陈明胜; 林春; 周锐; 杨惠安; 江晓燕; 潘晨; 李东良

doi:10.3969/j.issn.1001-5256.2016.07.014

替比夫定初治慢性乙型肝炎患者早期病毒学应答预测模型的建立

DOI: 10.3969/j.issn.1001-5256.2016.07.014

1. 福建医科大学孟超肝胆医院传染科
2. 福建医科大学福总临床医院肝胆内科

基金项目:

艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2012ZX10002-004)；福建中医药大学校管科研课题(XB2013078)；福州市科技计划项目(SF-109);福州市科技计划项目(2014-S-W26)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2170
- HTML全文浏览量: 21
- PDF下载量: 452
- 被引次数: 0
出版历程
- 收稿日期: 2016-01-28
- 出版日期: 2016-07-20

Establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B patients treated with telbivudine

Research funding:

摘要

摘要: 目的早期病毒学应答可以预测核苷酸类药物治疗的长期疗效,拟建立替比夫定初治慢性乙型肝炎（CHB）患者早期病毒学应答预测模型。方法收集2007年1月-2014年8月于福建医科大学孟超肝胆医院就诊的CHB患者135例,接受替比夫定（600 mg,1次/d）治疗至少24周,每2周进行1次随访,记录患者基线资料及治疗过程中的检测数据。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验,Cox比例风险回归模型分析早期病毒学应答的影响因素,并建立预测模型。结果无HBV感染家族史（P=0.000 3）、较高基线TBil（P=0.002 6）和AST（P=0.007 4）水平、较低水平的HBV DNA载量（P=0.002 3）更可能出现早期病毒学应答。根据这些变量建立预测模型,在24周时共有18例患者取得早期病毒学应答,受试者工作特征曲线下面积为62.3%,95%可信区间为38.8%85.9%（P=0.049）,最佳临界值为0.85。CHB患者的风险评分>0.85的CHB患者更可能获得早期病毒学应答。结论通过家族史以及基线TBil、AST和HBV ...
- 肝炎,乙型,慢性 /
- 替比夫定 /
- 比例危险度模型 /
- 预测
Abstract: Objective To investigate the establishment of a predictive model for early virologic response in previously untreated chronic hepatitis B( CHB) patients treated with telbivudine,since early virologic response can predict the long- term efficacy of nucleotide analogues.Methods A total of 135 CHB patients who visited Mengchao Hepatobiliary Hospital of Fujian Medical University from January 2007 to August 2014 were enrolled and treated with telbivudine( 600 mg qd) for at least 24 weeks. Follow- up was performed once every 2 weeks,and the patients' baseline data and data measured during treatment were recorded. The t- test was used for comparison of continuous data between groups,the chi- square test was used for comparison of categorical data between groups,and the Cox proportional hazards regression model was used to analyze the influencing factors for early virologic response and establish the predictive model. Results The patients without a family history of hepatitis B virus( HBV) infection( P = 0. 000 3) and with high baseline levels of total bilirubin( TBil)( P = 0. 002 6)and aspartate aminotransferase( AST)( P = 0. 007 4) and a low HBV DNA load( P = 0. 002 3) tended to show early virologic response.The predictive model was established based on these variables,and the risk score( R) of CHB patients was calculated. The CHB patients with R > 0. 85 were more likely to achieve early virologic response. Conclusion The model established based on the four variables of family history,baseline TBil level,baseline AST level,and HBV DNA level can well predict early virologic response in previously untreated CHB patients treated with telbivudine.
- hepatitis B /
- chronic /
- telbivudine /
- proportional hazards models

HTML全文

参考文献(14)

[1]XU JB.AntiviraI effect of telbivudine in patients with chronic hepatitis B[J].J Pract Hepatol,2010,13(5):374-375.(in Chinese)徐俊斌.替比夫定治疗慢性乙型肝炎的疗效观察[J].实用肝脏病杂志,2010,13(5):374-375.

[2]LIU XD.Telbivudine[J].Chin J Med Chemistry,2007,17(5):335.(in Chinese)刘晓东.替比夫定(telbivudine)[J].中国药物化学杂志,2007,17(5):335.

[3]NGUYEN MH,KEEFFE EB.Chronic hepatitis B:early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides[J].J Viral Hepat,2009,16(3):149-155.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].Clin JHepatol,2011,19(1):13-24.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.

[5]YOU CR,LEE SW,JANG JW,et al.Update on hepatitis B virus infection[J].World J Gastroenterol,2014,20(37):13293-13305.

[6] SHI XF,HONG GL.A survey of the status of hepatitis B virus infection in people undergoing physical examination[J].Int J Virol,2015,22(Suppl):58-59.(in Chinese)石新芳,鸿嘎鲁.健康体检人员乙肝病毒感染状况调查[J].国际病毒学杂志,2015,22(Suppl):58-59.

[7]YU YQ,CHEN SL,ZHANG WH.Research progress in combination therapy with pegylated interferon and nucleos(t)ide analogues in treatment of chronic hepatitis B[J].J Clin Hepatol,2015,31(9):1513-1519.(in Chinese)喻一奇,陈少隆,张文宏.核苷和核苷酸类药物联合聚乙二醇干扰素治疗慢性乙型肝炎的研究进展[J].临床肝胆病杂志,2015,31(9):1513-1519.

[8]HUANG MX,WU YK,SHI H,et al.Comparation of the efficacy of telbivudine and entecavir for treating 144 weeks of patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(1):32-36.(in Chinese)黄明星,吴元凯,时红,等.替比夫定和恩替卡韦治疗慢性乙型肝炎144周的疗效比较[J/CD].中华实验和临床感染病杂志:电子版,2014,8(1):32-36.

[9]WU Y,HAN L,YUAN YF.Meta-analysis of telbivudine and lamivudine in the treatment of chronic hepatitis B[J].China Med Herald,2014,11(28):11-13.(in Chinese)吴岩,韩璐,原永芳.替比夫定和拉米夫定治疗慢性乙型肝炎的Meta分析[J].中国医药导报,2014,11(28):11-13.

[10]SUN DC,CHEN L,WU ZY,et al.Current status of diagnosis and treatment of chemotherapy-associated hepatitis B virus reactivation[J].Chin J Clin Pharmacol,2014,19(5):584-590.(in Chinese)孙德聪,陈丽,吴志勇,等.化疗相关乙肝病毒再激活的诊治现状[J].中国临床药理学与治疗学,2014,19(5):584-590.

[11]LIAW YF,GANE E,LEUNG N,et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.

[12]YUEN MF,FONG DY,WONG DK,et al.Hepatitis B virus DNAlevels at week 4 of lamivudine treatment predict the 5-year ideal response[J].Hepatology,2007,46(6):1695-1703.

[13]BROOK MG,KARAYIANNIS P,THOMAS HC.Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy?A statistical analysis of predictive factors[J].Hepatology,1989,10(5):761-763.

[14]MARINOS G,NAOUMOV NV,WILLIAMS R.Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection[J].Hepatology,1996,24(5):991-995.

施引文献

资源附件(0)

访问统计